<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409211</url>
  </required_header>
  <id_info>
    <org_study_id>17-00748</org_study_id>
    <nct_id>NCT03409211</nct_id>
  </id_info>
  <brief_title>Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis</brief_title>
  <acronym>PAMPPA</acronym>
  <official_title>Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof-of-principle, placebo-controlled, open label study to assess the improvement
      in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients
      with PsO (subjects may or may not have PsA) , who have active disease and are not currently
      receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy
      subjects.

      The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3
      weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be
      used during this period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in % of Treg Cells in Blood</measure>
    <time_frame>6 Weeks</time_frame>
    <description>% change in the expansion of regulatory T cells; demonstrate an increase in %Treg at 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Medium Chain Fatty Acids (MCFA) content in the stool</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change in the amount of MCFA in stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in skin disease severity (PASI scores)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>PASI 50, 75, 90 responses, indicating 50%, 75%, and 90% reductions, respectively, in WHATEVER PASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the tender joint/swollen joint (TJ/SJ) counts at 6 weeks.</measure>
    <time_frame>6 Weeks</time_frame>
    <description>To assess whether PEVCO 1000 mg four times daily for 6 weeks improves:
66/68 Tender-joint count
66/68 Swollen-joint count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Pso</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with or without PsA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Without PsA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PEVCO</intervention_name>
    <description>All subjects will receive PEVCO for 6 more weeks.</description>
    <arm_group_label>Pso</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <other_name>Coconut Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement Capsules without Coconut Oil</intervention_name>
    <description>All subjects will receive placebo (PBO) for 3 weeks</description>
    <arm_group_label>Pso</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an active [psoriatric plaque &gt;2cm

        Exclusion Criteria:

          -  History of sensitivity to study compound or any of their excipients

          -  Previous intolerance to PEVCO or related compounds

          -  Current (within 3 months of screening) treatment with DMARDs

          -  Current (within 3 months of screening) treatment with biologic therapies (including
             but limited to anti-TNF,anti-IL-17, anti-IL-12/23)

          -  Current antibiotic treatment (within 3 months of screening)

          -  current consumption of probiotics (within 3 months of screening)

          -  Severe hepatic impairment (eg, ac-sites and/or clinical signs of coagulopathy)

          -  Renal failure (eGFR ,30 or require dialysis) by history

          -  History of other autoimmune or inflammatory skin disease

          -  Current immunodeficiency state (cancer, HIV, others)

          -  Current immunodeficiency state (cancer, HIV, Other)

          -  Concern for inability of the patient to comply with study procedure, and or follow up
             (alcohol or drug abuse)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Scher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luz Alvarado</last_name>
    <phone>646-501-7400</phone>
    <email>Luz.Alvarado@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luz Alverado</last_name>
      <phone>646-501-7400</phone>
      <email>luz.alverado@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Jose U Scher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

